11.14.22
Kyowa Hakko USA brought immune and cognitive health to life at SupplySide West. The company featured its IMMUSE postbiotic and Cognizin citicoline through educational and interactive outreach.
IMMUSE is a clinically researched immune activator supported by nearly 30 published studies, including 14 human trials. IMMUSE delivers a breakthrough approach to comprehensive immune support through a novel method of action that utilizes a rare but key type of immune cells called plasmacytoid dendritic cells (pDC), which have been shown to activate cells that are pivotal to immune support, such as NK, Killer-T, Helper-T, and B cells.
Heather Moday, MD, author of "The Immunotype Breakthrough," spoke at SupplySide West and assisted audience members in determining their personal immunotypes. Moday explained how immunotypes can be used to identify individuals’ most effective methods of immune support and how IMMUSE’s unique mode of action can support that process—a mode of action discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd.
“Our body registers all stressors, including work, financial, and family stress just to name a few, in the same way as a real physical threat,” Moday said. “When you add up all of the small stressors that are constantly triggering our fight-or-flight response, it leads to changes in our immune system.”
Cognizin, Kyowa Hakko’s branded form of citicoline, is a potent brain health nutrient and nootropic that has been shown in clinical studies and human trials to support mental energy, focus, memory, and attention.
While other cognitive health ingredients may enhance brain performance, citicoline increases phosphatidylcholine, offering multifaceted benefits.
At SupplySide West, Kyowa Hakko emulated a clinical study that targeted e-gamers and was conducted by neuropsychologists using a variety of tests simulating cognitive functions and keyboard actions, including a finger tap test. Tradeshow attendees participated in the “Tap Challenge,” available through an app, to see how quickly they could tap a button over a 20-second timeframe.
“We debuted this app at SxSW and it was a hit,” said Karen Todd, vice president of global brand marketing, Kyowa Hakko USA, Inc. “We had the same positive response at SupplySide West, and we were excited to bring the benefits of Cognizin to life for the researchers and innovators behind the next big nutraceuticals and functional foods and beverages.”
Cognizin is currently available in more than 200 products on the market globally.
Kyowa Hakko plans to continue educating industry and consumers on the benefits of IMMUSE and Cognizin throughout 2023 alongside its other branded ingredients, including Setria Gluathione, Pantesin Pantethine, VELOX Patented Performance Blend, and EYEMUSE Lacticaseibacillus paracasei KW3110.
IMMUSE is a clinically researched immune activator supported by nearly 30 published studies, including 14 human trials. IMMUSE delivers a breakthrough approach to comprehensive immune support through a novel method of action that utilizes a rare but key type of immune cells called plasmacytoid dendritic cells (pDC), which have been shown to activate cells that are pivotal to immune support, such as NK, Killer-T, Helper-T, and B cells.
Heather Moday, MD, author of "The Immunotype Breakthrough," spoke at SupplySide West and assisted audience members in determining their personal immunotypes. Moday explained how immunotypes can be used to identify individuals’ most effective methods of immune support and how IMMUSE’s unique mode of action can support that process—a mode of action discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd.
“Our body registers all stressors, including work, financial, and family stress just to name a few, in the same way as a real physical threat,” Moday said. “When you add up all of the small stressors that are constantly triggering our fight-or-flight response, it leads to changes in our immune system.”
Cognizin, Kyowa Hakko’s branded form of citicoline, is a potent brain health nutrient and nootropic that has been shown in clinical studies and human trials to support mental energy, focus, memory, and attention.
While other cognitive health ingredients may enhance brain performance, citicoline increases phosphatidylcholine, offering multifaceted benefits.
At SupplySide West, Kyowa Hakko emulated a clinical study that targeted e-gamers and was conducted by neuropsychologists using a variety of tests simulating cognitive functions and keyboard actions, including a finger tap test. Tradeshow attendees participated in the “Tap Challenge,” available through an app, to see how quickly they could tap a button over a 20-second timeframe.
“We debuted this app at SxSW and it was a hit,” said Karen Todd, vice president of global brand marketing, Kyowa Hakko USA, Inc. “We had the same positive response at SupplySide West, and we were excited to bring the benefits of Cognizin to life for the researchers and innovators behind the next big nutraceuticals and functional foods and beverages.”
Cognizin is currently available in more than 200 products on the market globally.
Kyowa Hakko plans to continue educating industry and consumers on the benefits of IMMUSE and Cognizin throughout 2023 alongside its other branded ingredients, including Setria Gluathione, Pantesin Pantethine, VELOX Patented Performance Blend, and EYEMUSE Lacticaseibacillus paracasei KW3110.
